Mumbai, Feb. 25 -- Biocon has received approval from the U.S. FDA, for its complex formulation Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda(R)).

Published by HT Digital Content Services with permission from Capital Market....